Results 271 to 280 of about 1,261,208 (309)
Some of the next articles are maybe not open access.
Sensitivity analysis of progression‐free survival with dependent withdrawal
Statistics in Medicine, 2008AbstractWe develop a sensitivity analysis method for comparing treatment‐specific distributions where the endpoint is progression‐free survival (PFS). The censoring process may be informative due to selective patient withdrawal, which occurs whenever disease evaluation has been discontinued without progression being documented. The sensitivity analysis
Ping K, Ruan, Robert J, Gray
openaire +2 more sources
Elacestrant Prolongs Progression-Free Survival in Advanced Breast Cancer
Cancer Discovery, 2022Abstract Prolonged progression-free survival was seen with elacestrant versus standard-of-care endocrine therapy.
openaire +2 more sources
Alternatives to the Kaplan–Meier estimator of progression-free survival
The International Journal of Biostatistics, 2020Abstract Progression-free survival (PFS), defined as the time from randomization to progression of disease or death, has been indicated as an endpoint to support accelerated approval of certain cancer drugs by the U.S. FDA. The standard Kaplan–Meier (KM) estimator of PFS, however, can result in significantly biased estimates.
Zhang, Jenny J. +3 more
openaire +2 more sources
Relationship Between Progression-Free Survival and Overall Survival Benefit: A Simulation Study
Therapeutic Innovation & Regulatory Science, 2013This study evaluated the circumstances under which the observed progression-free survival (PFS) benefit may translate into an overall survival (OS) benefit.A simulation study, based on PFS and OS joint model decomposition, was conducted to evaluate the impact of crossover rates, survival post progression (SPP) lengths, and magnitudes of difference in ...
Lijun, Zhang +3 more
openaire +2 more sources
Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer
Journal of Clinical Oncology, 2007Purpose The traditional end point for assessing efficacy of first-line chemotherapies for advanced cancer is overall survival (OS), but this end point requires prolonged follow-up and is potentially confounded by the effects of second-line therapies. We investigated whether progression-free survival (PFS) could be considered a valid surrogate for OS in
Marc, Buyse +8 more
openaire +2 more sources
Health insurance status and cancer stage at diagnosis and survival in the United States
Ca-A Cancer Journal for Clinicians, 2022Jingxuan Zhao +2 more
exaly
Valid Analysis of Brain-Specific Progression-Free Survival
JAMA OncologyYuandong, Yu, Fengjun, Cao, Guoxing, Wan
openaire +4 more sources
PL03.12 Progression Free Survival and Overall Survival in NADIM II Study
Journal of Thoracic Oncology, 2022M. Provencio +26 more
openaire +1 more source